News Incyte's PD-1 drug brings immunotherapy to anal cancer Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
News ESMO: Incyte's PD-1 treads new ground in anal cancer Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programm